We are pleased to annouce the signing of a Distribution Agreement with BioTNS. This Agreement allows AVATAMED to offer the COVID-19 RT-PCR PNA Diagnostic Kits worldwide, and adds to AVATAMED growing portfolio of infectious disease-related Healthcare products.
Please view the Press Releases:
http://www.sisanewszine.co.kr/news/articleView.html?idxno=11284
http://www.koreabiz.org/news/view.php?idx=26645&mcode=msub1
The molecular diagnostic kit developed by TNS is a reagent that amplifies and detects the amount of virus gene through reverse transcription polymerase chain reaction (RT-PCR), and has been approved for emergency use by the U.S. Food and Drug Administration (FDA). The biggest advantage of the COVID-19 PT-PCR PNA KIT is the improved sensitivity and precision by 2 to 5 times, compared to other diagnostic kits, resulting in very low false positives and false negatives.
Please visit www.avatahealthcare.com for more information.
